Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Roche Stories

2011-02-16 00:00:00

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze((TM) technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin® SC (trastuzumab), to enter a Phase 3 registration study as...

2011-02-07 15:30:00

PRINCETON, N.J., Feb. 7, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended December 31, 2010. Financial Results Revenues were $0.2 million during the quarter ended December 31, 2010 compared to $0.3 million for the quarter ended December 31, 2009 and include...

2011-02-01 10:29:00

MANNHEIM, Germany, Feb. 1, 2011 /PRNewswire/ -- An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.(1) Self-monitoring of blood glucose...

2010-12-03 09:02:00

Focus on cancer vaccines, auto-immune disease diagnostics and treatment DALLAS, Dec. 3, 2010 /PRNewswire-USNewswire/ -- Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI. These programs will leverage BIIR's...

2010-11-23 15:56:00

PRINCETON, N.J., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2010. At fiscal year end Pharmasset held $127.1 million in cash and cash equivalents. Pipeline Update and 2010 highlights RG7128 Phase 2b PROPEL and JUMP-C trials...

2010-11-05 06:30:00

SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the third quarter ended September 30, 2010. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO) "Halozyme...

2010-10-11 15:05:00

SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram...

2010-10-04 07:00:00

NUTLEY, N.J. and BASEL, Switzerland Oct. 4 /PRNewswire/ -- Roche announced today that Jacques Banchereau, Ph.D., has joined Roche as Senior Vice President and Head of the Inflammation and Virology Discovery and Translational Areas (DTAs). In this role, he will oversee research and early development up to late stage development in the field of Inflammation, including autoimmune and respiratory diseases such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD) as well...

2010-09-20 08:00:00

NUTLEY, N.J., Sept. 20 /PRNewswire/ -- In an effort to stimulate local business activity and encourage its employees to build a deeper connection with the communities in which they work, today, Roche, in partnership with the North Jersey Regional Chamber of Commerce/Clifton Economic Develop Assistance Commission (CEDAC) and the Nutley Chamber of Commerce (NCoC), is launching the "Roche Goes to Town" program in Nutley and Clifton, New Jersey. Roche has provided each of its full-time New...

2010-08-04 12:49:00

IPSWICH, Mass., Aug. 4 /PRNewswire/ -- New England Biolabs is pleased to announce that Canada's Michael Smith Genome Sciences Center has selected New England Biolabs as one of its key suppliers for next-generation sequencing library construction reagents. NEBNext DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited and validated for sample preparation for next generation sequencing, as well as the preparation of expression libraries. Reagents are available for...